Multiple Sclerosis - KOL Insight

This report provides a comprehensive analysis of the current and future landscape of multiple sclerosis (MS) therapies, focusing on the decline of oral disease-modifying therapies (DMTs) and the rise of higher-efficacy treatments. It examines the market dynamics of key therapies like Zeposia, Mavenclad, and Tysabri, and explores the potential of emerging treatments such as masitinib and tolebrutinib.

Key questions answered:

• 1. What events are impacting the uptake of oral DMTs?
• 2. How are therapies perceived by the medical community in terms of efficacy, tolerability, and ease of administration?
• 3. Which recently completed or ongoing clinical trials have the greatest potential to affect prescribing trends?
• 4. What will DMTs need to show to become the treatment of choice in specific therapy lines?
• 5. How will the use of each current and pipeline DMT change in the future in terms of line of therapy and preference?
• 6. What will pipeline products need to show in terms of efficacy and tolerability to compete with current therapies?
• 7. Which pipeline products are the most promising, and how will they impact current market players?
• 8. How will the treatment landscape for MS evolve in the future for each patient segment and line of therapy?

Key brands covered in this report:

Companies: